EHC · Encompass Health Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 1, 2022; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Discharges | 68,895 | Q2 2026 | — |
|
|
|||
| Net patient revenue per discharge | $22,521 | Q2 2026 | — |
|
|
|||
| Same-store discharge growth | 2.8% | Q2 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $335.6M | Q4 2025 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 346M
+30.2M Interest expense and amortization of debt discounts and fees
-0.3M Loss/gain on sale of investments, excluding impairments
+0.8M Equity in net income of nonconsolidated affiliates
-57M Net income attributable to noncontrolling interests in continuing operations
-2.4M Amortization of debt-related items
-2.7M Distributions from nonconsolidated affiliates
+36.3M Current portion of income tax expense
-13.9M Change in assets and liabilities
-1.1M Cash (provided by) used in operating activities of discontinued operations
-0.4M Change in fair market value of marketable securities
+0.1M Other
= Adjusted EBITDA 335.6M
|
|||
| Adjusted free cash flow non-GAAP | $235.4M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EHC
this stock
Encompass Health Corp
|
$12.19B | +16.4% | +10.5% | 20.1 | 3.7% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 1, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EHC | -1.3% | +10.1% | +16.4% | +11.3% | +16.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.7% | +5.7% | +2.7% | +7.4% | +2.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.